Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 13 studies. IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up P1081: 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT DAIDS Number 10770 Research Area Mother to child transmission Study Status Concluded 1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed 1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed 1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed P1039: A Randomized Trial of ZDV/3TC/ABC vs. ZDV/3TC/LPV/r DAIDS Number 10046 Research Area Other Study Status Concluded P1032: Prevention of Development of Nevirapine-Resistance Mutations in Postpartum Women DAIDS Number 10137 Research Area Other Study Status Concluded Pagination Current page 1 Page 2 Next page Next
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling
P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up
P1081: 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT DAIDS Number 10770 Research Area Mother to child transmission Study Status Concluded
1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed
1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
P1039: A Randomized Trial of ZDV/3TC/ABC vs. ZDV/3TC/LPV/r DAIDS Number 10046 Research Area Other Study Status Concluded
P1032: Prevention of Development of Nevirapine-Resistance Mutations in Postpartum Women DAIDS Number 10137 Research Area Other Study Status Concluded
